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STATE-OF-THE-ART PAPERDSTATE-OF-THE-ART PAPER761Adiponectin and Vulnerable Atherosclerotic PlaquesAilin Barseghian, Dipika Gawande, Mandeep Bajaj
Adiponectin is an adipocytokine that is reduced in subjects with obesity and type 2 diabetes.
Hypoadiponectinemia has been associated with an increased risk of coronary artery disease
and acute coronary syndrome (ACS) in several, although not all, studies. Adiponectin has
been shown to decrease the progression of atherosclerosis by inhibiting both neointimal
thickening and smooth muscle cell proliferation and migration to the intima in vivo. Lower
adiponectin levels have been associated with higher necrotic core ratio in both culprit and
nonculprit lesions in patients with ACS on virtual histology intravascular ultrasound imaging.
Barseghian and colleagues review the pathological significance of adiponectin and its potential
as a therapeutic target.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
771oubling of Clopidogrel Dose Improves Platelet Inhibition,
Endothelial Function, and Markers of InflammationGiuseppe Patti, Domenico Grieco, Giordano Dicuonzo, Vincenzo Pasceri, Annunziata Nusca,
Germano Di Sciascio
The ARMYDA-150 (Antiplatelet Therapy for Reduction of Myocardial Damage During
Angioplasty) trial compared the effects of high or standard clopidogrel maintenance doses on
platelet inhibition, inflammation, and endothelial function in patients undergoing
percutaneous coronary intervention. A total of 50 patients were randomized 1 month after
intervention to receive standard (75 mg/day) or high (150 mg/day) clopidogrel maintenance
dose for 30 days and then crossed over to the other dose. Patients receiving 150 mg/day had
higher platelet inhibition, better flow-mediated dilation (FMD), and lower high-sensitivity
C-reactive protein levels. Larger trials powered for clinical outcomes may be warranted to
compare the efficacy of high clopidogrel maintenance dosing.(continued on page A-24)
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779revalence and Predictors of Concomitant
Carotid and Coronary Artery Atherosclerotic DiseaseArie Steinvil, Ben Sadeh, Yaron Arbel, Dan Justo, Anca Belei, Natan Borenstein, Shmuel Banai, Amir Halkin
Steinvil and colleagues evaluated the relationship between coronary and carotid atherosclerotic
disease by performing a retrospective analysis of patients undergoing same-day coronary
angiography and carotid Doppler studies. The study included 1,405 patients, of whom 13%
had a significant carotid artery stenosis (CAS) (peak systolic velocity [PSV] 125 cm/s) and
4.6% had a severe CAS (PSV 230 cm/s). The severity of CAS and the extent of coronary
artery disease (CAD) were significantly correlated. Independent predictors of severe CAS
defined by PSV were the presence of left main or 3-vessel CAD, increasing age, a history of
stroke, smoking status, and diabetes mellitus. The frequency and severity of carotid stenosis
correlates with the extent of CAD.ATHEROSCLEROSIS784The Cost-Effectiveness of Applying the JUPITER Trial Results Into Clinical PracticeNiteesh K. Choudhry, Amanda R. Patrick, Robert J. Glynn, Jerry Avorn
The JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin) trial found that rosuvastatin reduces vascular events in subjects with
elevated high-sensitivity C-reactive protein (hs-CRP) but normal low-density lipoprotein
(LDL) cholesterol levels. Choudhry and colleagues studied the implications of expanding
treatment recommendations based on these results with a cost-effectiveness model. Among
patients with LDL 130 mg/dl and hs-CRP levels 2.0 mg/l, rosuvastatin had an
ncremental cost-effectiveness of $25,198 per quality-adjusted life year (QALY) gained
ompared with usual care. Implementing this strategy only in patients with a Framingham
isk score 10% yielded an incremental cost-effectiveness of $14,205 per QALY. This
trategy would become cost-saving if the price of rosuvastatin was $0.86 per day.ditorial Comment: Mark Hlatky, p. 792HEART RHYTHM DISORDERS: VIEWPOINT794Systematic Review Finds Limited Data on the Incidence of SCD in the United StatesMelissa H. Kong, Gregg C. Fonarow, Eric D. Peterson, Anne B. Curtis, Adrian F. Hernandez,
Gillian D. Sanders, Kevin L. Thomas, David L. Hayes, Sana M. Al-Khatib
Consistent and current data on the incidence of sudden cardiac arrest (SCA) and/or sudden
cardiac death (SCD) may help improve risk stratification and prevention measures. Kong and
colleagues performed a systematic review of previous studies that estimated the incidence of
SCA/SCD in the United States. Only 6 primary sources of data were identified, with a wide
range in the estimated annual incidence of SCD from 180,000 to 450,000. These different
estimates were due to different data sources, definitions of SCD, and methods of estimation/
extrapolation. This systematic review suggests the need for standardized definitions of SCA
and SCD and reliable methods for ascertaining the data.(continued on page A-26)
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The short QT syndrome (SQTS) is a cardiac channelopathy associated with atrial fibrillation
and sudden cardiac death. Gollob and colleagues reviewed the literature to develop diagnostic
criteria for SQTS. A total of 61 reported cases of SQTS were identified. The cohort had a
mean corrected QT interval of 299 ms, with values ranging from 248 to 349 ms in
symptomatic cases. A diagnostic scoring system was developed from these cases, which
includes electrocardiographic parameters, clinical history, family history, and genotype. These
formal diagnostic criteria will facilitate diagnostic evaluation in suspected cases of SQTS and
may lead to a greater recognition of this rare disease entity.HEART RHYTHM DISORDERS
813ardiac Resynchronization Therapy Is More Effective in Women Than in Men:
Results From the MADIT-CRT TrialAysha Arshad, Arthur J. Moss, Elyse Foster, Luigi Padeletti, Alon Barsheshet, Ilan Goldenberg,
Henry Greenberg, W. Jackson Hall, Scott McNitt, Wojciech Zareba, Scott Solomon, Jonathan S. Steinberg,
on behalf of the MADIT-CRT Executive Committee
In this report, Arshad and colleagues reviewed data from the MADIT-CRT (Multicenter
Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) trial
and the relationship between sex and outcomes after cardiac resynchronization therapy with a
defibrillator (CRT-D). Female patients were more likely to have nonischemic cardiomyopathy
and left bundle branch block. Female patients had a better result from CRT-D therapy than
males, with a significant 70% reduction in heart failure and a 72% reduction in all-cause
mortality. These beneficial CRT-D effects in women were associated with greater
echocardiographic evidence of reverse cardiac remodeling in women than men. These results
show a stronger benefit for CRT-D therapy in women than in men; the authors speculate
that a QRS duration 130 ms, which was one of the study entry criteria, may indicate more
ventricular dyssynchrony in women than in men, who normally have a longer QRS.(continued on page A-28)
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821yocardial Fibrosis on CMR Predicts
Appropriate Device Therapy in Patients With ICDsLeah Iles, Heinz Pfluger, Lisa Lefkovits, Michelle J. Butler, Peter M. Kistler, David M. Kaye,
Andrew J. Taylor
Iles and colleagues evaluated the association between regional myocardial fibrosis and
ventricular arrhythmias in patients with cardiomyopathies. A total of 103 patients meeting
criteria for implantable cardioverter-defibrillator (ICD) implantation for primary prevention of
sudden cardiac death underwent cardiac magnetic resonance imaging (CMR) prior to device
implantation. Regional fibrosis was identified with late gadolinium enhancement (LGE).
LGE identified regional fibrosis in one-half of the patients with nonischemic cardiomyopathy
(NICM) and in all patients with ischemic cardiomyopathy. There was a 29% discharge rate
in the NICM group with LGE compared with no ICD discharges in the NICM group
without LGE. Patients with advanced cardiomyopathy and myocardial fibrosis demonstrated
by LGE on CMR have a high likelihood of appropriate ICD therapy. Correspondingly, the
absence of LGE may indicate a lower risk for malignant ventricular arrhythmias.Editorial Comment: James T. Willerson, p. 829HEART RHYTHM DISORDERS831LA Fibrosis Detected by DE-MRI Associated With Risk of Stroke in Patients With AFMarcos Daccarett, Troy J. Badger, Nazem Akoum, Nathan S. Burgon, Christian Mahnkopf,
Gaston Vergara, Eugene Kholmovski, Christopher J. McGann, Dennis Parker, Johannes Brachmann,
Rob S. MacLeod, Nassir F. Marrouche
Daccarett and colleagues sought to determine the association between left atrial (LA) fibrosis,
detected using delayed-enhancement magnetic resonance imaging (DE-MRI), and the
CHADS2 score variables, specifically stroke. The degree of LA fibrosis was determined as a
percent of the LA area in almost 400 subjects. More LA fibrosis was seen in those with a
history of stroke. A logistic regression analysis demonstrated that LA fibrosis independently
predicted cerebrovascular events and significantly increased the predictive performance of the
CHADS2 score. These results suggest that the amount of DE-MRI–determined LA fibrosis
is a marker for stroke risk in patients with atrial fibrillation (AF).(continued on page A-36)
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ECARDIAC IMAGING839Impaired LVSV Reserve With Dobutamine Stress Predicts Risk of Pulmonary EdemaCharaslak Charoenpanichkit, William C. Little, Sangeeta Mandapaka, Erica Dall’Armellina,
Timothy M. Morgan, Craig A. Hamilton, W. Gregory Hundley
Charoenpanichkit and colleagues studied whether several markers of cardiac performance
obtained with cardiac magnetic resonance (CMR) imaging during dobutamine stress would
identify patients at risk for subsequent hospitalization with pulmonary edema. Left ventricular
stroke volume (LVSV), ventriculovascular stiffness (pulse pressure/LVSV index), and aortic
distensibility were measured at rest and during intravenous dobutamine infusion. Participants
with a reduced ratio of stress/rest LVSV, an increased ventriculovascular stiffness stress/rest
ratio, and a reduced stress-induced measure of aortic distensibility were more likely to
experience an episode of pulmonary edema. LVSV reserve and the stress/rest
ventriculovascular stiffness ratio remained significant after multivariable adjustment. In
patients without inducible ischemia during dobutamine stress, a failure to increase LV stroke
volume or an increase in ventriculovascular stiffness indicates a higher risk for subsequent
pulmonary edema.HEART FAILURE AND BIOMARKERS849Novel Measures of Renal Dysfunction Predict Long-Term Risks in Patients With HFSergio Manzano-Ferna´ndez, James L. Januzzi, Jr, Miguel Boronat-Garcia, Juan Carlos Bonaque-Gonza´lez,
Quynh A. Truong, Francisco J. Pastor-Pérez, Carmen Muñoz-Esparza, Patricia Pastor,
Marı´a D. Albaladejo-Oto´n, Teresa Casas, Mariano Valdés, Domingo A. Pascual-Figal
-trace protein (BTP) and cystatin C are newer biomarkers for renal dysfunction that may
more accurately reflect renal function. Manzano-Ferna´ndez and colleagues evaluated the
prognostic significance of these biomarkers in patients with acutely destabilized heart failure
(ADHF). Neither BTP nor cystatin C were associated with worsening renal function during
the index hospitalization. Those with adverse outcomes had higher BTP and cystatin C.
After multivariable adjustment, both BTP and cystatin C were significant predictors of death/
heart failure (HF) hospitalization, whereas serum creatinine, estimated glomerular filtration
rate (GFR), and blood urea nitrogen were no longer significant. In patients with normal renal
dysfunction defined as an estimated GFR 60 ml/min, elevated concentrations of BTP and
ystatin C were still associated with a higher risk of adverse clinical events. Among patients
ospitalized with ADHF, BTP and cystatin C predict risk for death and/or HF
ospitalization and are superior to standard measures of renal function for this indication.
ditorial Comment: Horng H. Chen, p. 859(continued on page A-38)
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861entraxin 3 is a New Inflammatory Marker Correlated With
Left Ventricular Diastolic DysfunctionJunichi Matsubara, Seigo Sugiyama, Toshimitsu Nozaki, Koichi Sugamura, Masaaki Konishi, Keisuke Ohba,
Yasushi Matsuzawa, Eiichi Akiyama, Eiichiro Yamamoto, Kenji Sakamoto, Yasuhiro Nagayoshi,
Koichi Kaikita, Hitoshi Sumida, Shokei Kim-Mitsuyama, Hisao Ogawa
Pentraxin 3 (PTX3) is a novel inflammatory marker and a member of the pentraxin
superfamily that includes C-reactive protein (CRP). Matsubara and colleagues investigated
the clinical significance of PTX3 levels in patients with heart failure with normal ejection
fraction (HFNEF). The levels of PTX3, tumor necrosis factor-, and interleukin-6, but not
high-sensitivity CRP, were significantly higher in HFNEF patients than non-heart failure
(HF) patients. PTX3 levels in the coronary sinus were significantly higher than the aortic root
in HFNEF patients but not in non-HF patients without diastolic dysfunction. PTX3 is
elevated in HFNEF patients and is produced in the coronary circulation in patients with
diastolic dysfunction.EXPEDITED PUBLICATIONS EXPEDITED PUBLICATIONS
870-3 PUFAs Improve LV Function and Functional Capacity
in Patients With Dilated CardiomyopathySavina Nodari, Marco Triggiani, Umberto Campia, Alessandra Manerba, Giuseppe Milesi,
Bruno M. Cesana, Mihai Gheorghiade, Livio Dei Cas
Nodari and colleagues tested the effects of n-3 polyunsaturated fatty acids (PUFAs) on left
ventricular (LV) systolic function in patients with nonischemic dilated cardiomyopathy
(NICM). Subjects on standard therapy were randomized to 2 g of n-3 PUFAs or placebo for
12 months. Subjects assigned to PUFAs had significant increases in LV ejection fraction,
peak VO2, exercise duration, and mean New York Heart Association functional class. Given
hese promising results, larger studies appear warranted to study the benefits of PUFAs for
atients with NICM.ditorial Comment: W. H. Wilson Tang, Michael A. Samara, p. 880
